SUPERNUS PHARMACEUTICALS INC's ticker is and the CUSIP is 868459AD0. A total of 46 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $46,902,000 | +1.4% | 46,902,000 | 0.0% | 3.79% | -5.0% |
Q4 2022 | $46,257,098 | +0.9% | 46,902,000 | 0.0% | 3.99% | -6.0% |
Q3 2022 | $45,824,000 | +0.2% | 46,902,000 | 0.0% | 4.24% | -3.5% |
Q2 2022 | $45,737,000 | -1.5% | 46,902,000 | 0.0% | 4.40% | +17.6% |
Q1 2022 | $46,433,000 | +2.8% | 46,902,000 | +3.3% | 3.74% | +9.2% |
Q4 2021 | $45,147,000 | +0.7% | 45,402,000 | 0.0% | 3.42% | -18.6% |
Q3 2021 | $44,828,000 | +21.0% | 45,402,000 | +21.6% | 4.21% | +5.9% |
Q2 2021 | $37,062,000 | +2.0% | 37,347,000 | 0.0% | 3.97% | -10.4% |
Q1 2021 | $36,345,000 | -1.7% | 37,347,000 | -3.7% | 4.44% | +7.7% |
Q4 2020 | $36,963,000 | -4.5% | 38,801,000 | -7.2% | 4.12% | -13.0% |
Q3 2020 | $38,713,000 | +3.6% | 41,818,000 | +99876.1% | 4.74% | -25.8% |
Q2 2020 | $37,385,000 | +10.9% | 41,828 | +2.0% | 6.39% | -7.6% |
Q1 2020 | $33,718,000 | +287.5% | 41,026 | +329.1% | 6.91% | +427.8% |
Q4 2019 | $8,701,000 | – | 9,562 | – | 1.31% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Wellesley Asset Management | 71,162 | $69,799,000 | 4.72% |
ZAZOVE ASSOCIATES LLC | 27,692,000 | $27,021,000 | 2.38% |
ADVENT CAPITAL MANAGEMENT /DE/ | 61,727,000 | $60,252,000 | 1.17% |
SHENKMAN CAPITAL MANAGEMENT INC | 7,637,000 | $7,524,000 | 0.85% |
NN Investment Partners Holdings N.V. | 38,700,000 | $37,743,000 | 0.30% |
CAMDEN ASSET MANAGEMENT L P /CA | 5,825,000 | $5,684,000 | 0.18% |
EDMOND DE ROTHSCHILD HOLDING S.A. | 4,479,000 | $4,384,000 | 0.16% |
Lombard Odier Asset Management (Europe) Ltd | 2,005,000 | $1,905,000 | 0.16% |
PRUDENTIAL PLC | 41,809,000 | $40,973,000 | 0.12% |
Calamos Advisors LLC | 22,303,000 | $21,829,000 | 0.12% |